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Abstract
Background: Among the members of the ATP binding cassette transporter superfamily, MRPs
share the closest homology with the CFTR protein, which is defective in CF disease. MRP1 has been
proposed as a potential modifier gene and/or as novel target for pharmacotherapy of CF to explain
the clinical benefits observed in some CF patients treated with the macrolide AZM. The 5'UTR of
the MRP1 gene contains a GCC triplet repeat that could represent a polymorphic site and affect
the activity of the promoter.
Methods: The MRP1 5' flanking region was amplified by PCR from 36 CF patients and 100 non-CF
subjects and the number of GCC triplets of each allele was determined by sequence and
electrophoretic analysis. We performed gene reporter studies in CF airway epithelial cells
16HBE14o-AS3, in basal conditions and in the presence of AZM.
Results: We found that the GCC repeat is polymorphic, ranging from 7 to 14 triplets either in CF
or in non-CF subjects. Our data are preliminary and have to be confirmed on a larger population
of CF subjects. The transcriptional activity of the proximal MRP1 5' regulatory region revealed no
statistically significant correlations between the number of repeats and treatment with AZM.
Conclusion: We identified a novel polymorphism in the 5'UTR of MRP1 gene that provides
multiple alleles in a gene relevant for multidrug resistance as well as for CF, determining that this
region is transcriptionally active and that this activity does not appear to be influenced by AZM
treatment.
Background
CF is an autosomal recessive disease primarily manifested
in the lung, which leads to respiratory failure. CF is caused
by mutations of the CFTR gene whose product acts as a
cAMP-activated chloride channel that is permeable to
organic anions, including GSH [1,2]. A wide range of dis-
ease severities has been described, even among CF
patients harbouring the same mutation. Therefore endog-
enous factors, that modulate or complement CFTR func-
tion, must exist. Because of the structural homology
between CFTR and MRP1, a functional complementation
of CFTR defect by MRP1 has been hypothesized [3].
Induction of MRP1 expression has been suggested to be
responsible for improvement in lung function in a CF
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patient following chemotherapy with cyclophosphamide
and epirubicin [4]. Low levels of MRP1 transcripts have
been associated with more severe CF phenotype [5], while
increased expression of the MRP1 gene has been associ-
ated with restored chloride conductance in a group of CF
patients following treatment with AZM, giving rise to clin-
ical beneficial effects [6,7]. MRP1 has been considered as
a potential modifier gene [5] and/or as a target for therapy
of CF in subjects responsive to AZM [8].
The MRP1 was originally cloned in a drug-selected lung
cancer cell line [9]. MRPs are transmembrane proteins,
whose mRNAs are detectable in most human tissues [10].
They share the closest homology with the CFTR protein,
which belongs to the same C subfamily of the ABC trans-
porter superfamily [11]. MRP1 confers resistance to chem-
otherapeutic drugs as well as to heavy metal oxyanions. It
transports reduced glutathione conjugates, cysteinyl leu-
kotriene LTC4, steroid glucoronides and bile salt deriva-
tives in human cells, agents involved in the transcription
factor NF-kB activation pathway, which has been reported
to be altered in CF [12,13]. Therefore a functional link
exists between genes involved in GSH metabolism and
MRP1. NF-kB regulates expression of GSTP1 and poly-
morphisms of the anti-oxidizing enzymes GSTP1 and
GSTM3 are associated with severity of CF [14]. The
GSTM1 gene, encoding an enzyme that forms glutathione
adducts, is deleted in most severe CF patients [15]. CF
patients carrying a wild type allele for both GSTM1 and
GSTT1 may be at reduced risk of severe lung disease. The
abnormal reduced glutathione transport caused by CFTR
mutation seems to play a critical role in the pathogenesis
of CF and this parameter might also be complemented by
MRP1 in CF patients. MRP1 has been also involved in the
regulation of endogenous channels as chloride channels
[16,17]. The physiological functions of MRP1 are the sub-
ject of many current investigations: the available evidence
indicates that it is involved in detoxification, drug resist-
ance, oxidative stress and inflammation [18,19]. An
impaired response to inflammatory stimuli has been
described in MRP1(-/-) knockout mice [20], even if MRP1
has not been demonstrated to be a disease-causing gene.
The sequence of the MRP1 gene has been reported [9]. The
5' flanking region is GC rich (88%) while the 5'UTR con-
tains a GCC triplet repeat that has been hypothesized to
represent a polymorphic site [12]. The influence of the
number of triplets in the 5'UTR on MRP1 mRNA tran-
scription, stability and translational efficiency has not
been determined.
We searched a genetic marker for MRP1 with potential
functional relevance aiming to establish: 1) whether the
GCC repeat in the MRP1 5'UTR is polymorphic, 2) if the
GCC triplets length could affect the activity of the pro-
moter in CF airways epithelial cells either in basal condi-
tions or upon AZM treatment.
Methods
Patients and controls
Genomic DNA from 100 unrelated non-CF subjects and
36 CF patients was collected. Nucleic acid was extracted
from peripheral blood leukocytes using the salting out
method [21]. Diagnosis of CF was based on clinical, bio-
chemical and genetic data. The most common CF causing
mutation, deltaF508, was detected in 24 patients, 7 of
which were homozygous. This study was approved by the
local institutional Ethic Committee.
Genotyping
Specific primers were designed based on the nucleotide
sequence of the 5' regulatory region of MRP1 gene (Gen-
Bank:U07050) (sequences are available upon request).
PCRs were performed in an Applied Biosystems 9700
Thermal Cycler, using a final volume of 50 µl. Due to the
high GC levels of the PCR products, 7-deaza-dGTP
(Roche) was utilized instead of dGTP in the dNTPs mix.
PCR-1 started with 350 ng of genomic DNA; 2.5 µl of
PCR-1 were subjected to further amplification (PCR-2)
and a third round of amplification (PCR-3) was per-
formed with 2.5 µl of PCR-2. Amplifications were carried
out starting with 10 min template denaturation/AmpliTaq
Gold (Applied Biosystems) activation step at 95°C, fol-
lowed by 40 cycles (20 cycles for PCR-3) of denaturation
at 95°C for 30 s, annealing at 58°C for 30 s and extension
Table 1: MRP1(GCC)n alleles frequencies in non-CF and CF subjects
Number of GCC triplets Alleles in non-CF subjects (%) Alleles in CF patients (%)
73 2 2 9
10 3 0
11 16 21
12 13 10
13 31 38
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at 72°C for 30 s. As a final product the fragment from -337
nt to -43 nt, starting from the translational starting site of
the MRP1 5' gene, was obtained.
PCR products were purified with the NucleoSpin Extract
kit (Macherey-Nagel). Samples were then sequenced
using Thermo Sequenase II Dye Terminator Cycle
Sequencing Premix Kit (Amersham Biosciences) and the
automated 373A DNA Sequencer (Applied Biosystems).
PCR-3 was carried out in the presence of a primer conju-
gated to FAM dye (5-carboxyfluorescein) (Applied Biosys-
tems) that generated labelled amplicons suitable for
electrophoresis and Genescan analysis.
Genescan analysis Software (Applied Biosystems) was
used to determine the length of the PCR products. In
order to validate our method we utilized a vector includ-
ing the MRP1 (GCC)7 allele (kind gift from Roger Deeley,
Queen's University, Kingston, Ontario, Canada) as con-
trol. A proof-reading enzyme was utilized and at least
duplicates of each sample and control vector were per-
formed to exclude polymerase slippage.
Gene reporter studies
The MRP1 5' regulatory region containing 7 or 14 GCC tri-
plets, obtained as PCR-3 product, was cloned in the pGL3
vector (Promega). The constructs were checked by restric-
tion, sequence and Genescan analysis and named
MRP1(GCC)7-luc or MRP1(GCC)14-luc, according to the
number of triplets. The CF airway epithelial cell line
16HBE14o-AS3 (kind gift from Pamela Davis, Case West-
ern Reserve University School of Medicine, Cleveland,
OH, USA) was transiently co-transfected using FUGENE
(Roche) with the reporter vector MRP1(GCC)7-luc or
MRP1(GCC)14-luc and a beta-gactosidase expressing vec-
tor, utilized for normalization. The day after the transfec-
tion, cells were incubated for 24 hrs with or without AZM
8 µg/ml (Pfizer Italia). This concentration is consistent
with that achieved in the lung of CF patients treated with
AZM [22]. Luciferase activity was determined using the
Luciferase Assay System (Promega) according to the man-
ufacturer's instructions. Luciferase activity in insert-less
(pGL3) transfected cells was almost undetectable.
Results
The MRP1 5' flanking region is polymorphic
The MRP1 5' flanking region was amplified by PCR from
36 CF patients and 100 non-CF subjects and the number
of triplets of each allele was determined by sequencing
and electrophoretic analysis.
In non-CF subjects the number of triplets ranged from 7
triplets to 14. Six distinct alleles consisting of 7, 10, 11, 12,
13 and 14 GCC triplets were found. The frequencies of
these MRP1(GCC)n alleles, where n indicates the number
of triplets, is shown in Table 1. The genotypes frequencies
of the GCC alleles are indicated in Table 2.
Assessment of transcriptional activity
In order to establish whether the length of the GCC repeat
can affect the transcriptional activity we performed gene
reporter studies in CF airway epithelial cells 16HBE14o-
AS3. This region has been previously demonstrated to be
transcriptionally active by gene reporter studies [9]. Since
the clinical status as well as the response to AZM has been
associated to the levels of MRP1 mRNA in CF patients, we
tested the transcriptional activity of MRP1 in our model
by gene reporter assays in the presence or absence of the
drug. The levels of luciferase activity measured in the con-
Table 2: Genotypes frequencies of the MRP1(GCC)n alleles in the control group and in the CF patients
Genotype % in non-CF subjects % in CF subjects
7/7 23 25
13/13 15 6
7/13 12 0
11/12 10 11
11/13 9 0
12/13 7 28
7/11 5 6
12/12 4 3
11/11 3 0
14/14 3 0
10/11 2 8
10/13 2 0
10/14 2 0
13/14 2 2
7/14 1 0
12/14 0 8
7/12 0 3BMC Medical Genetics 2006, 7:7 http://www.biomedcentral.com/1471-2350/7/7
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structs containing 7 or 14 GCC triplets of the MRP1 5' reg-
ulatory region were not significantly modified (p > 0.05)
either in basal conditions or in the presence of AZM (Fig-
ure 1).
Discussion
This study demonstrates that the genomic region from -
337 nt to -43 nt of the MRP1 5' regulatory region includes
a polymorphic site and possesses transcriptional activity.
We also demonstrate that the MRP1(GCC)7 and
MRP1(GCC)14 alleles (chosen as representative of the
shortest and longest triplet length we identified) do not
show any statistically significant differences in transcrip-
tional activity when tested in CF airway epithelial cells in
vitro. We chose these two alleles since we hypothesized
that the length of the GCC repeat could influence MRP1
transcriptional activity as suggested by other authors [9].
Since we have been focusing to a partial region of the
5'UTR of the MRP1 gene, our approach was not aimed to
test the influence of upstream regulatory sites eventually
associated with specific GCC(n) alleles, as a recently
described G/C single nucleotide polymorphism [23].
The number of alleles described in our limited group of
CF subjects does not allow for searching genotype-pheno-
type correlation. Efforts are in progress in order to perform
this analysis. Our data are preliminary and have to be con-
firmed on a larger population of CF subjects.
We show that AZM treatment does not affect reporter gene
activity in either of the tested alleles. Therefore, at least
under the experimental conditions we utilized in our
assays, the sequence responsible for variable levels of
MRP1 detected in other studies [5,8] does not appear to
be included in the DNA sequence we analyzed. Previous
studies reported that multiple Sp-1 binding domains are
located close to MRP1 transcriptional start sites near the
GCC repeat and might participate in the modulation of
transcriptional activity. Zhu and Center [9] suggested a
variable length of the GCC repeat in the MRP1 5' regula-
tory region and proposed the influence of this sequence
on the MRP1  mRNA transcription. In support of this
hypothesis, it has been reported that a triple GCC repeat
within the 5' flanking region contributes to the regulation
of interleukin 1 alpha expression [24]. As Slapak and col-
leagues demonstrated that MRP1  gene amplification is
not sufficient for explaining drug resistance [25], the pol-
ymorphism we identified might be utilized for investigat-
ing whether the number of GCC triplets could be
associated with this feature. However, we still cannot
exclude a functional relevance of this polymorphism on
MRP1 mRNA transcription, stability and/or translational
efficiency in its native context.
Conclusion
In summary we established that: 1) the GCC repeat in the
MRP1 5'UTR is polymorphic, 2) the GCC triplets length
do not affect in vitro the activity of the promoter in CF air-
ways epithelial cells either in basal conditions or upon
AZM treatment.
We propose our experimental for testing whether other
molecules potentially relevant for therapy of CF have the
capability to influence MRP1 gene expression acting on
this promoter region.
Finally, the polymorphic length of the GCC repeat we
described can be exploited as a genetic marker, possibly
linked to additional sequences involved in regulation of
constitutive or induced MRP1 expression.
List of abbreviations
AZM azithromycin
CF cystic fibrosis
CFTR cystic fibrosis transmembrane conductance regula-
tor
Comparison of the transcriptional activity of MRP1 alleles  containing 7 or 14 GCC triplets Figure 1
Comparison of the transcriptional activity of MRP1 
alleles containing 7 or 14 GCC triplets. 16HBE14o-AS3 
cells were transfected with reporter vectors including the 
MRP1 5'UTR region with 7 [MRP1(GCC)7-luc] or 14 triplets 
[(GCC)14-luc] driving the luciferase gene. 16HBE14o-AS3 
cells transfected with MRP1(GCC)7-luc and not treated with 
AZM were considered as calibrator. Percentages of luci-
ferase activity normalized with beta galactosidase are shown. 
Specificity of the signal was assessed by determining the luci-
ferase activity in insert-less (pGL3) transfected cells, which 
was almost undetectable. Experiments were performed in 
triplicate (n = 3, p > 0.05 for all conditions, paired T-Test; 
SEMs are indicated by bars).
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